Last update :
19/11/2024
Anticancer drug   Panitumumab  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Vectibix Argentina, Australia, Belgium, Canada, Chile, Denmark, Ecuador, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey, United States of America
References   injection   References : Panitumumab  
Type Publication
2296 Manufacturer Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3135 Journal Ikesue H, Vermeulen LC, Hoke R, Kolesar JM.
Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags.
Am J Health-Syst Pharm 2010 ; 67, 3: 223-226.
4807 Manufacturer Vectibix 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics Updated 13-Jul-2023
Amgen Ltd 2023
4819 Journal Carpanese D, Rossi V, Di Paolo V, Quintieri L, Penna Zuccolotto G, Sebellin J, Saran C, Pipitone F, Miolo G, de Diana E et al.
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.
Int J Pharm 2024 ; 649: 123643.

  Mentions Légales